CRNX Jan 2025 60.000 call
| Previous close | 6.30 |
| Open | N/A |
| Bid | 0.95 |
| Ask | 4.70 |
| Strike | 60.00 |
| Expiry date | 2025-01-17 |
| Day's range | 6.30 - 6.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 8 |
GuruFocus.comInsider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ...
Chief Scientific Officer Stephen Betz of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) sold 3,000 shares of the company on June 10, 2024, according to a recent SEC Filing.
GlobeNewswireCrinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements ma
Investor's Business DailyCrinetics Unveils 'Stunning' Results In Highly Anticipated Study
Crinetics unveiled "stunning" results from a study of a major drug. Crinetics stock rose Monday.
